Source comparison
BPC-157 Help Achilles Tendonitis: Comparison of Evidence Sources
Rodent RCTs (Achilles transection models) High internal validity 72% faster tensile strength recovery at 14 days; increased VEGF and Type I collagen deposition Species differences; dose scaling unverified; surgical injury ≠ chronic tendinosis Mechanism is real
This comparison does not assign a generated winner or score.
- Rodent RCTs (Achilles transection models)
- High internal validity
- 72% faster tensile strength recovery at 14 days; increased VEGF and Type I collagen deposition
- Species differences; dose scaling unverified; surgical injury ≠ chronic tendinosis
- Mechanism is real but human translation unproven
- Human anecdotal reports
- Low. No controls, subjective endpoints
- Reported pain reduction within 2–4 weeks at 250–500mcg/day subcutaneous
- Placebo effect, publication bias, variable product purity, no imaging confirmation of healing
- Consistent pattern suggests signal but lacks rigor
- In vitro studies (cultured fibroblasts)
- Moderate. Controlled conditions
- Enhanced collagen gene expression (COL1A1) and fibroblast proliferation at nanomolar concentrations
- Cell culture ≠ whole organism; no immune or vascular components
- Supports mechanism but insufficient alone
- Regulatory status
- N/A
- Not FDA-approved; no IND filed; no Phase 1 safety trials in humans
- Legal gray area. Sold 'for research only'; purity/potency unverified
- Users assume risk without safety data
- Comparative peptide data (TB-500, GHK-Cu)
- Low to moderate
- TB-500 (Thymosin Beta-4) has one Phase 2 trial for tendon injury (non-Achilles); no head-to-head with BPC-157
- Different mechanisms; TB-500 targets actin dynamics, BPC-157 targets angiogenesis
- BPC-157 may work synergistically but no data
- The evidence hierarchy places BPC-157 far below FDA-approved treatments like eccentric loading protocols (Level 1 evidence for tendinosis) and shockwave therapy (Level 2 evidence). It sits in a category of 'biologically plausible but clinically unverified'. Similar to platelet-rich plasma (PRP) before rigorous trials demonstrated mixed outcomes.